Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

Journal of Medicinal Chemistry

Volumn 39, Issue 3, 1996, Pages 673-679

  Brickner, Steven J ^a   Hutchinson, Douglas K ^a   Barbachyn, Michael R ^a   Manninen, Peter R ^a   Ulanowicz, Debra A ^a   Garmon, Stuart A ^a   Grega, Kevin C ^a   Hendges, Susan K ^a   Toops, Dana S ^a   Ford, Charles W ^a   Zurenko, Gary E ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (5 HYDROXYMETHYL 2 OXO 3 OXAZOLIDINYL)BENZENESULFONAMIDE; BACTERIAL PROTEIN; E 3709; EPEREZOLID; LINEZOLID; N [[3 (4 ACETYLPHENYL) 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; N [[3 [4 (METHYLSULFINYL)PHENYL] 2 OXO 5 OXAZOLIDINYL]METHYL]ACETAMIDE; OXAZOLIDINONE DERIVATIVE; U 97456; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG SYNTHESIS; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; ORAL DRUG ADMINISTRATION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; STAPHYLOCOCCUS; STREPTOCOCCUS;

ACETAMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; DOGS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICROBIAL SENSITIVITY TESTS; OXAZOLES; OXAZOLIDINONES; RATS;

EID: 0030027833     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9509556     Document Type: Article

References (46)

1. Swartz, M. N. Hospital-acquired Infections: Diseases with Increasingly Limited Therapies. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 2420-2427.
2. Tomasz, A. Multiple-Antibiotic-Resistant Pathogenic Bacteria. N. Engl. J. Med. 1994, 330, 1247-1251.
3. Fekete, T. Bacterial Genetics, Antibiotic Usage, and Public Policy: The Crucial Interplay in Emerging Resistance. Perspect. Biol. Med. 1995, 38, 363-382.
4. Courvalin, P. Transfer of Antibiotic Resistance Genes Between Gram-Positive and Gram-Negative Bacteria. Antimicrob. Agents Chemother. 1994, 1447-1451.
5. Low, D. E.; Willey, B. M.; McGeer, A. J. Multidrug-resistant Enterococci: a Threat to the Surgical Patient. Am. J. Surg. 1995, 5A (Suppl.), 8S-12S.
6. Spera, R. V., Jr.; Farber, B. F. Multidrug-Resistant Enterococcus faecium: An Untreatable Nosocomial Pathogen. Drugs 1994, 48, 678-688.
7. Boyce, J. M.; Opal, S. M.; Chow, J. W.; Zervos, M. J.; Potter-Bynoe, G.; Sherman, C. B.; Romulo, R. L. C.; Fortna, S.; Medeiros, A. Outbreak of Multidrug-Resistant Enterococcus faecium with Transferable vanB Class Vancomycin Resistance. J. Clin. Microbiol. 1994, 1148-1153.
8. Jones, R. N.; Sader, H. S. The Clinical Impact of Enterococcal Resistance. Challanges Infect. Dis. 1993, 1, 1-5.
9. Brumfitt, W.; Hamilton-Miller, J. M. T. The Challenge of Methicillin-Resistant Staphylococcus aureus. Drugs Exp. Clin. Res. 1994, XX, 215-224.
10. Neu, H. C. Quinolone Antimicrobial Agents. Annu. Rev. Med. 1992, 43, 465-468.
11. Blumberg, H. M.; Rimland, P.; Carroll, D. J.; Terry, P.; Wachsmuth, I. K. Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and -Resistant Staphylococcus aureus. J. Infect. Dis. 1991, 163, 1279-1285.
12. Neu, H. C. Infection Problems for the 1990's - Do We have an Answer? Scand. J. Infect. Dis. 1993 (Suppl. 91), 7-13.
13. Barrett, J. F. Meeting Highlights First International Conference on Antibiotic Resistance: Impact on Discovery. Exp. Opin. Invest. Drugs 1994, 3 (11), 1227-1230.
14. Noble, W. C.; Virani, Z.; Cree, R. G. A. Co-transfer of Vancomycin and Other Resistance Genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 1992, 93, 195-198.
15. Silver, L. L.; Bostian, K. A. Discovery and Development of New Antibiotics: the Problem of Antibiotic Resistance. Antimicrob. Agents Chemotker. 1993, 377-383.
16. Appelbaum P. C. Antimicrobial Resistance in Streptococcus pneumoniae: An overview. Clin. Infect. Dis. 1992, 15, 77-83.
17. Fugitt, R. B.; Luckenbaugh, R. W. 5-Halomethyl-3-Phenyl-2-Oxazotidinones. U.S. Patent 4,128,654, Dec. 5, 1978.
18. Gregory, W. A. P-Oxooxazolidinylbenzene Compounds as Antibacterial Agents. U.S. Patent No. 4,461,773, July 24, 1984.
19. Daly, J. S.; Eliopoulos, G. M.; Willey, S.; Moellering, R. C., Jr. Mechanism of Action and In Vitro and In Vivo Activities of S-6123, a New Oxazolidinone Compound. Antimicrob. Agents Chemother. 1988, 32, 1341-1346.
20. Gregory, W. A.; Brittelli, D. R.; Wang, C. L.; Wuonola, M. A.; McRipley, R. J.; Eustice, D. C.; Eberly, V. S.; Bartholomew, P. T.; Slee, A. M.; Forbes, M. Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. J. Med. Chem. 1989, 32, 1673-1681.
21. Gregory, W. A. Aminomethyl Oxooxazolidinyl Benzenes Useful as Antibacterial Agents. U.S. Patent 4,705,799, Nov. 10, 1987.
22. Slee, A. M.; Wuonola, M. A.; McRipley, R. J.; Zajac, I.; Zawada, M. J.; Bartholomew, P. T.; Gregory, W. A.; Forbes, M. Oxazolidinones, A New Class of Synthetic Antibacterials: In Vitro and In Vivo Activities of DuP 105 and DuP 721. Abstracts of 27th Interscience Conference on Antimicrobial agents and Chemotherapy, New York, NY, Oct. 4-7, 1987; Abstract No. 244.
23. Eustice, D. C.; Feldman, P. A.; Zajac, I.; Slee, A. M. Mechanism of Action of DuP 721: Inhibition of an Early Event during Initiation of Protein Synthesis. Antimicrob. Agents Chemother. 1988, 32, 1218-1222.
24. Slee, A. M.; Wuonola, M. A.; McRipley, R. J.; Zajac, I.; Zawada, M. J.; Bartholomew, P. T.; Gregory, W. A.; Forbes, M. Oxazolidinones, a New Class of Synthetic Antibacterial Agents: In Vitro and In Vivo Activities of DuP 105 and DuP 721. Antimicrob. Agents Chemother. 1987, 31, 1791-1797.
25. Ashtekar, D. R.; Costa-Periera, R.; Shrinivasan, T.; Iyyer, R.; Vishvanathan, N.; Rittel, W. Oxazolidinones, a New Class of Synthetic Antituberculosis Agent. Diagn. Microbiol. Infect. Dis. 1991, 14, 465-471.
26. Brumfitt, W.; Hamilton-Miller, J. In Vitro Activity of DuP 105 and 721, New Synthetic Antimicrobial Agents. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, 1987; Abstract 241.
27. Pharmcast-International, February, 1995; 7-1-484, 487.
28. R. C. Piper, T. F. Platte, J. R. Palmer, unpublished, The Upjohn Co.
29. Brickner, S. J. 5′-Indolinyl-5-Beta-Amidomethyloxazolidin-2-ones. U.S. Patent 5,164,510, Nov. 17, 1992.
30. Carlson, R. K.; Park, C.-H.; Gregory, W. A. U.S. Patent 4,948,-801, Aug. 14, 1990.
31. Hutchinson, D. K.; Barbachyn, M. R.; Brickner, S. J.; Buysse, J. M.; Demyan, W.; Ford, C. W.; Garmon, S. A.; Glickman, S. E.; Grega, K. C.; Hendges, S. K.; Kilburn, J. O.; Manninen, P. R.; Reid, R. J.; Toops, D. S.; Ulanowicz, D. A.; Zurenko, G. E. Piperazinyl Oxazolidinones: Structure Activity Relationships of a New Class of Oxazolidinone Antibacterial Agents. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Paper F207.
32. Barbachyn, M. R.; Brickner, S. J.; Ford, C. W.; Glickman, S.; Grega, K. C.; Hendges, S. K.; Kilburn, J. O.; Toops, D. S.; Ulanowicz, D. A.; Zurenko, G. E. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Paper F206.
33. Gregory, W. A.; Brittelli, D. R.; Wang, C. L.; Wuonola, M. A.; McRipley, R. J.; Eustice, D. C.; Eberly, V. S.; Bartholomew, P. T.; Slee, A. M.; Forbes, M. Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group. J. Med. Chem. 1989, 32, 1673.
34. Herweh, J. E.; Kauffmann, W. J. 2-Oxazolidones via the Lithium Bromide Catalyzed Reaction of Isocyanates with Epoxides in Hydrocarbon Solvents. Tetrahedron. Lett. 1971, 809-812. Speranza, G. P.; Peppel, W. J. Preparation of Substituted 2-Oxazolidones from 1,2-Epoxides and Isocyanates. J. Org. Chem 1958, 23, 1922.
35. Herweh, J. E.; Kauffmann, W. J. 2-Oxazolidones via the Lithium Bromide Catalyzed Reaction of Isocyanates with Epoxides in Hydrocarbon Solvents. Tetrahedron. Lett. 1971, 809-812. Speranza, G. P.; Peppel, W. J. Preparation of Substituted 2-Oxazolidones from 1,2-Epoxides and Isocyanates. J. Org. Chem 1958, 23, 1922.
36. Wang, C.-L. J.; Gregory, W. A.; Wuonola, M. A. Chiral Synthesis of DuP 721, A New Antibacterial Agent. Tetrahedron 1989, 1323-1326.
37. Model studies have demonstrated the tandem sequence of alkylation, cyclization (with liberation of LiOBn), and butyl ester cleavage ensues as the temperature rises above ca. 15 °C.
38. Prior use of urethanes and epoxides to synthesize 3-alkyl- or 3-unsubstituted oxazolidinones are known, for example, reactions run neat, catalyzed by (a) tertiary amines: Iwakura, Y.; Izawa, S.-I. Glycidyl Ether Reactions with Urethanes and Ureas. A New Synthetic Method for 2-Oxazolidones. J. Org. Chem. 1964, 29, 379. (b) Lithium amide: Markley, F. X.; Horton, R. L.; Weinberger, K. A. 5-Aryloxymethyl-2-oxazolidinones. French Patent Addn. 80,105, March 22, 1963; Chem. Abstr. 1963, 59, 10058.
39. Prior use of urethanes and epoxides to synthesize 3-alkyl- or 3-unsubstituted oxazolidinones are known, for example, reactions run neat, catalyzed by (a) tertiary amines: Iwakura, Y.; Izawa, S.-I. Glycidyl Ether Reactions with Urethanes and Ureas. A New Synthetic Method for 2-Oxazolidones. J. Org. Chem. 1964, 29, 379. (b) Lithium amide: Markley, F. X.; Horton, R. L.; Weinberger, K. A. 5-Aryloxymethyl-2-oxazolidinones. French Patent Addn. 80,105, March 22, 1963; Chem. Abstr. 1963, 59, 10058.
40. Enantiomeric purity levels were determined using a Chiralcel OJ column (Daicel Chemical Industries, Ltd., Tokyo).
41. Zurenko, G. E.; Yagi, B. H.; Schaadt, R. D.; Allison, J. W.; Hutchinson, D. K.; Barbachyn, M. R.; Brickner, S. J. In Vitro Antibacterial Activity of U-100592 and U-100766, Novel Oxazolidinone Antibiotics. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstract F216.
42. Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Manninen, P. R.; Toops, D. S.; Ulanowicz, D. A.; Kilburn, J. O.; Glickman, S. E.; Zurenko, G. E.; Ford, C. W. Synthesis of U-100592 and U-100766, Two New Oxazolidinone Antibacterial Agents in Clinical Trials for Treatment of Multiply Resistant Gram Positive Infections. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstract F208.
43. Martin, I. J.; Daley-Yates, P. T. The Metabolism and Kinetics of a Novel Oxazolidinone, U-100592. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstract F222.
44. (a) Piper, R. C.; Lund, J. E.; Denlinger, R. H.; Platte, T. F.; Brown, W. P.; Brown, P. K.; Palmer, J. R. Drug Safety Evaluation of U-100592, an Oxazolidinone Antibiotic, In Dogs and Rats. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstract F223.
45. (b) Koike, S.; Miura, H.; Nakamura, R.; Chiba K.; Moe, J. B. Drug Safety Studies with a Novel Oxazolidinone, U-100766. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstract F224.
46. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptability Tests for Bacteria that Grow Aerobically-Third Edition; approved Standard; NCCLS Document M7-A3 (ISBN 1-56238-209-8); NCCLS: 771 Lancaster Ave., Villanova, PA 19085, 1993.